Top Page
COSMO Pharmaceuticals N.V.
(LSE:COPN)
COSMO Pharmaceuticals N.V. (COPN) vs. iShares MSCI Switzerland ETF (EWL)
COSMO Pharmaceuticals N.V. Business Overview & Revenue Model
COSMO Pharmaceuticals N.V. Financial Statement Overview
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 78.17M | 92.78M | 102.09M | 65.07M | 60.95M | 62.49M | Gross Profit |
| 41.76M | 53.44M | 83.33M | 49.93M | 50.51M | 53.25M | EBIT |
| 19.20M | 6.15M | 28.06M | 33.11M | 2.06M | -12.31M | EBITDA |
| 29.29M | 19.70M | 47.49M | 40.48M | 7.84M | -7.02M | Net Income Common Stockholders |
| 35.28M | -4.93M | 17.23M | 21.67M | -7.90M | -24.49M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 268.21M | 50.27M | 240.95M | 222.21M | 212.85M | 268.21M | Total Assets |
| 585.16M | 553.98M | 759.59M | 805.56M | 596.16M | 585.16M | Total Debt |
| 164.84M | 1.84M | 173.60M | 169.92M | 168.14M | 164.84M | Net Debt |
| 54.45M | -48.44M | -12.23M | -28.64M | -17.79M | 54.45M | Total Liabilities |
| 191.43M | 124.94M | 295.80M | 292.88M | 196.04M | 191.43M | Stockholders Equity |
| 393.73M | 422.16M | 456.93M | 505.28M | 400.13M | 393.73M |
| Cash Flow | Free Cash Flow | ||||
| 9.73M | 18.31M | 25.92M | 4.11M | 4.90M | -36.16M | Operating Cash Flow |
| 15.50M | 33.62M | 33.23M | 12.61M | 12.98M | -18.85M | Investing Cash Flow |
| 60.34M | 42.30M | 1.69M | 24.86M | 75.45M | -48.69M | Financing Cash Flow |
| -44.98M | -211.27M | -46.13M | -27.25M | -11.88M | -34.46M |
COSMO Pharmaceuticals N.V. Technical Analysis
COSMO Pharmaceuticals N.V. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | CHF613.65M | 7.87 | ― | 32.30% | 631.04% | ||
73 Outperform | CHF1.01B | 7.76 | 29.55% | 3.26% | 182.25% | ― | |
66 Neutral | $153.70M | 10.90 | ― | 450.19% | ― | ||
65 Neutral | $902.68M | ― | -6.44% | ― | 125.11% | 69.27% | |
54 Neutral | $5.31B | 3.28 | -45.10% | 2.80% | 16.76% | 0.02% | |
47 Neutral | $120.72M | ― | -40.40% | ― | -66.82% | 4.14% | |
44 Neutral | $134.06M | 2.58 | -93.91% | ― | -62.17% | -166.33% |
COSMO Pharmaceuticals N.V. Corporate Events
Cosmo Pharmaceuticals N.V. announced the approval of all agenda items at its 2025 general meeting, with shareholders endorsing a 2.5% increase in dividend distribution to EUR 2.05 per share. This decision reflects the company’s commitment to creating long-term value for its stakeholders, as emphasized by the Board Chairman and CEO. The company also plans to provide further insights into its projects at the upcoming Investor Day in Zurich.
The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF113.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.
Cosmo Pharmaceuticals is actively participating in Digestive Disease Week® 2025 in San Diego, focusing on AI and gastrointestinal drug development. The event serves as a platform for Cosmo to engage with key opinion leaders and potential partners, aiming to strengthen its position in AI-powered endoscopy and GI therapeutics. By convening its AI advisory board, Cosmo demonstrates its commitment to advancing GI care through technology and strategic partnerships, potentially benefiting doctors and patients globally.
Cosmo Pharmaceuticals announced that Endovision Limited has received EU-MDR certification for Cerebro, a real-time AI-powered guide for esophagogastroduodenoscopy (EGD) procedures. This certification marks a significant advancement in endoscopic imaging, enhancing examination quality and treatment outcomes. The Cerebro software, integrated into the Medtronic GI Genius™ system, uses advanced algorithms to improve the quality of upper gastrointestinal tract interventions, complementing existing solutions for the lower tract. This development aligns with Cosmo’s strategy to integrate AI into clinical practice, offering substantial benefits for patient care and positioning the company as a pioneer in AI-driven endoscopy.
Cosmo Pharmaceuticals has confirmed its financial forecast for 2025 remains unchanged despite a recent CHMP statement on the marketing authorization application for Winlevi® in Europe. While disappointed, the company is confident in Winlevi®’s clinical potential and is preparing to request a re-examination, emphasizing its commitment to ensuring patient access in Europe.
Cosmo Pharmaceuticals has announced its intention to appeal a negative recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use regarding the marketing authorization of Winlevi® (Clascoterone Cream 1%) for treating acne vulgaris in Europe. The decision was based on a negative benefit-risk assessment for adolescents, despite positive results in adults. Cosmo argues that the assessment did not appropriately differentiate between these age groups and emphasizes the product’s established safety and efficacy in both clinical studies and real-world use, particularly in the USA. The company remains confident in Winlevi’s potential as a treatment option and plans to engage with the EMA to ensure broader access across Europe.
Cosmo Pharmaceuticals has published the agenda for its General Meeting 2025, scheduled for May 30 in Amsterdam. Key items include the approval of the 2024 annual report, a proposal to distribute 2.05 EUR per share from reserves, and the election of board members. This meeting is a platform for reviewing achievements, discussing priorities, and engaging with shareholders, reflecting the company’s commitment to transparency and stakeholder engagement.
Cosmo Pharmaceuticals N.V. has appointed Federico Sommariva as its new Chief Legal Counsel. With extensive experience in the life sciences industry, Sommariva is expected to guide the company through regulatory challenges and support its strategic growth. His appointment is seen as a significant addition to Cosmo’s leadership team, enhancing its capability to navigate the evolving legal landscape and achieve long-term objectives.
Cosmo Pharmaceuticals has released its 2024 annual report, highlighting strong financial performance, exceptional revenue growth, and strategic progress. The company proposes a dividend increase to EUR 2.05 per share and plans to engage with stakeholders at an upcoming Investor Day. These developments underscore Cosmo’s commitment to sustainable growth and its strategic positioning in the pharmaceutical industry.